683274-50-2

Basic information

• Product Name: Benzenamine, 4-bromo-N-(1-methylethyl)-2-nitro-
• Synonyms: Benzenamine, 4-bromo-N-(1-methylethyl)-2-nitro-;4-Bromo-N-isopropyl-2-nitroaniline;N-(4-Bromo-2-nitrophenyl)-N-isopropylamine
• CAS NO: 683274-50-2
• Molecular Formula: C9H11BrN2O2
• Molecular Weight: 259
• Mol File: 683274-50-2.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Benzenamine, 4-bromo-N-(1-methylethyl)-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 4-bromo-N-(1-methylethyl)-2-nitro-(683274-50-2)
• EPA Substance Registry System: Benzenamine, 4-bromo-N-(1-methylethyl)-2-nitro-(683274-50-2)

Safety Data

• Hazardous Substances Data: 683274-50-2(Hazardous Substances Data)

Usage

Uses

N-Isopropyl 4-bromo-2-nitroaniline

Upstream product

• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 75-31-0 isopropylamine 

Downstream Products

• 1200114-01-7 5-bromo-1-isopropyl-1H-benzo[d]imidazole 

Relevant articles and documents

1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS

The present invention relates to lH-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

METHODS OF TREATING EPILEPSY USING THE SAME

The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of S1P1 receptor and methods of using the same for the treatment of seizures, epilepsy related conditions, epilepsy-related syndrome, and the like as described herein.

Nitrogen-containing bicyclic compounds and preparation method and use thereof

The present invention relates to nitrogen-containing bicyclic compounds and a preparation method and use thereof. The compounds or pharmaceutical compositions can be used as an inhibitor of retinoic acid-related orphan receptor gamma t (ROR gamma t). The invention also relates to the preparation method of the compounds and pharmaceutical compositions, and use of the in the compounds and pharmaceutical compositions in treatment or prevention of RORyt-mediated inflammatation or autoimmune diseases in mammals, particularly humans.